NEREA JAUREGIZAR ALBONIGAMAYOR-rekin lankidetzan egindako argitalpenak (9)

2023

  1. Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones

    Antibiotics, Vol. 12, Núm. 5

2022

  1. Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

    Journal of Fungi, Vol. 8, Núm. 7

2016

  1. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.

    International Journal of Antimicrobial Agents, Vol. 47, Núm. 3, pp. 178-183

2005

  1. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: An integrated parent-metabolite model

    Pharmaceutical Research, Vol. 22, Núm. 11, pp. 1769-1782

2003

  1. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: A population pharmacokinetic model

    Gerontology, Vol. 49, Núm. 4, pp. 205-214

2002

  1. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction

    European Journal of Clinical Pharmacology, Vol. 58, Núm. 9, pp. 615-619

  2. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats

    Journal of Pharmaceutical Sciences, Vol. 91, Núm. 1, pp. 41-52

  3. Prediction of unbound propofol concentrations in a diabetic population

    Therapeutic Drug Monitoring, Vol. 24, Núm. 6, pp. 689-695

2001

  1. Altered disposition and effect of lerisetron in rats with elevated alpha1-acid glycoprotein levels

    Pharmaceutical Research, Vol. 18, Núm. 6, pp. 838-845